December 5th 2024
The calcitonin gene-related peptide monoclonal antibody significantly reduced the number of monthly migraine days.
September 4th 2024
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
Navigating Parkinson Disease: Innovative Approaches to Mitigate OFF Episodes
1.0 Credit / Neurology
View More
The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Setti...
1.25 Credits / Neurology
View More
Addressing the Unmet Needs in the Management of Myasthenia Gravis: The Role of New and Emerging Therapies
1.5 Credits / Neurology
View More
In-Depth Insights and Application in the Management of Immunoglobulin Therapy
1.0 Credit / Neurology, Immunology
View More
Overview and Burden of Migraine
0.5 Credit / Neurology
View More
The Evolving Treatment Landscape of Migraine
0.5 Credit / Neurology
View More
Exploring Alternative Pain Management Strategies for Headaches and Migraines | AMCP Nexus 2024
October 23rd 2024New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.